Britain's National Health Service now offers teplizumab, a monoclonal antibody drug that delays the onset of type 1 diabetes by approximately three years. This marks the first time the NHS has funded a treatment specifically designed to slow the autoimmune destruction of insulin-producing cells before symptoms appear.
Teplizumab works by suppressing the immune system's attack on beta cells in the pancreas. The drug targets CD3 receptors on T cells, reducing their ability to damage insulin-producing tissue. Clinical trials showed that people at risk of developing type 1 diabetes who received teplizumab experienced a median delay of three years before needing insulin therapy compared to placebo recipients.
The drug becomes available to patients who have tested positive for diabetes-related autoantibodies, meaning their immune systems have already begun attacking pancreatic cells. These individuals face progression to clinical type 1 diabetes within months or years, depending on how many autoantibodies they carry. Early detection through screening identifies candidates for treatment before symptoms develop.
Type 1 diabetes develops when the immune system mistakenly destroys beta cells, leaving the body unable to produce insulin naturally. Previously, no intervention could slow this process. Patients discovered the disease only after symptoms appeared, when significant beta cell damage had already occurred. The three-year delay allows families more time to prepare and adjust to eventual insulin dependency, while children can complete critical developmental stages.
The NHS decision follows regulatory approval from the Medicines and Healthcare products Regulatory Agency. Access remains limited to people identified through autoantibody screening, as the treatment works only before clinical diabetes develops. Healthcare providers will identify eligible candidates through existing screening programs and diabetes clinics.
While teplizumab does not prevent type 1 diabetes, it fundamentally changes the disease timeline. The extra years without insulin use reduce complications and hospitalizations during that period. This represents